Top in endocrinology: Continuous glucose monitoring disruptions; updated dietary guidance
Click Here to Manage Email Alerts
Most adults with diabetes who used continuous glucose monitoring, or CGM, reported at least one disruption over the past year, with device malfunction and insertion problems being the most common reasons, data show.
“The vast majority of individuals using CGM are not getting the full wear time out of every CGM sensor,” Alexis M. McKee, MD, CDCES, an assistant professor of medicine at Washington University School of Medicine in St. Louis, told Healio.
It was the top story in endocrinology last week.
The second top story covered updated recommendations from the Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes, which emphasize that people with diabetes should limit eating meat and refined grains and increase consumption of whole grains, fruits, vegetables, legumes and nuts.
Read these and more top stories in endocrinology below:
Most adults with diabetes report CGM disruptions due to device problems, medical care
More than 80% of adults with diabetes using continuous glucose monitoring reported at least one instance of needing to stop using their device due to medical care or a device-related problem, according to survey findings. Read more.
European dietary guideline emphasizes whole grains, fruits and vegetables for diabetes
Dietary patterns focused on eating more whole grains, vegetables, fruits, legumes, nuts and seeds are best for the management of diabetes, according to an updated guideline published in Diabetologia. Read more.
Personalized approach emphasized in AACE consensus statement for treating type 2 diabetes
Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement. Read more.
FDA declines to OK palopegteriparatide for hypoparathyroidism over manufacturing concerns
The FDA has rejected a new drug application for an agent to treat adults with hypoparathyroidism due to concerns with manufacturing control strategy, according to an industry press release. Read more.
Setmelanotide reduces hyperphagia, improves quality of life in Bardet-Biedl syndrome
Treatment with the melanocortin-4 receptor agonist setmelanotide reduced hyperphagia and led to improvements in emotional well-being among children and adults with Bardet-Biedl syndrome, according to study findings. Read more.